Mental distress and subsequent use of anxiolytic drugs - A prospective population-based cohort study of 16,000 individuals

Scandinavian Journal of Public Health

Volumn 38, Issue 5, 2010, Pages 465-473

  Hausken, Anne M ^a   Furu, Kari ^a   Tverdal, Aage ^a   Skurtveit, Svetlana ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Anxiolytics; benzodiazepines; HSCL 10; mental distress symptoms; pharmacoepidemiology; population based; prospective studies

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE;

ADULT; ANXIETY; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NORWAY; PRESCRIPTION; PROGNOSIS; PROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICS;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; BENZODIAZEPINES; COHORT STUDIES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NORWAY; PROGNOSIS; PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS;

EID: 77954041596     PISSN: 14034948     EISSN: None     Source Type: Journal    
DOI: 10.1177/1403494810370229     Document Type: Article

References (29)

1. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2006. Geneva: WHO; 2005.
2. Alonso J., Angermeyer MC, Bernert S., Bruffaerts R., Brugha TS, Bryson H., et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 55-64.
3. The Norwegian Prescription Database. http://www.fhi.no/eway/default.aspx?pid=238&trg=MainArea_5811&MainArea_5811=5903:0:15,4440:1:0:0:::0:0 (accessed 15 March 2008).
4. NOMESCO Nordic Medico Statistical Committee. Medicines consumption in the Nordic Countries 1999-2003; 2004.
5. Demyttenaere K., Bonnewyn A., Bruffaerts R., De Girolamo G., Gasquet I., Kovess V., et al. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). J Affect Disord 2008; 110(1-2):84-93.
6. Laurier C., Dumas J., Gregoire JP Factors related to benzodiazepine use in Quebec -secondary analysis of survey data. J Pharmacoepidemiol 1992; 2(4):73-86.
7. Kassam A., Patten SB Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Popul Health Metr 2006;4: 15.
8. Lagnaoui R., Depont F., Fourrier A., Abouelfath A., Begaud B., Verdoux H., et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004; 60(7):523-9.
9. Hausken AM, Skurtveit S., Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Safety 2007; 16(8):913-18.
10. Blennow G., Romelsjo A., Leifman H., Leifman A., Karlsson G. Sedatives and hypnotics in Stockholm - social factors and kinds of use. Am J Public Health 1994; 84(2):242-6.
11. Hausken AM, Skurtveit S., Rosvold EO, Bramness JG, Furu K. Psychotropic drug use among persons with mental distress symptoms: a population-based study in Norway. Scand J Public Health 2007; 35(4):356-64.
12. Olfson M., Pincus HA Use of benzodiazepines in the community. Arch Intern Med 1994; 154(11):1235-40.
13. Ohayon MM, Lader MH Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002; 63(9):817-25.
14. O’Brien CP Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005; 66(Suppl 2):28-33.
15. Strand BH, Dalgard OS, Tambs K., Rognerud M. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry 2003; 57(2):113-18.
16. Naess O., Sogaard AJ, Arnesen E., Beckstrom AC, Bjertness E., Engeland A., et al. Cohort profile: cohort of Norway (CONOR). Int J Epidemiol 2008; 37(3):481-5.
17. The Oslo Health Study. Main questionnaire. http://www.fhi.no/dav/66091FDE33734FAB96849B26D9F46333.pdf (accessed 17 January 2006).
18. Derogatis LR, Lipman RS, Rickels K., Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974; 19(1):1-15.
19. Furu K., Skurtveit S., Rosvold E. Drug use questions in Norwegian health surveys - response rate and agreement between specific and open-ended questions. Nor J Epidemiol 2003; 13(1):147-54.
20. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 2008; 18(2):129-36.
21. Hosmer DW, Lemeshow S. Applied logistic regression, Second edn. New York: Wiley-Interscience; 2000.
22. Hausken AM, Furu K., Skurtveit S., Engeland A., Bramness JG Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol 2009; 65(3):295-301.
23. Mykletun A., Overland S., Aaro LE, Liabo HM, Stewart R. Smoking in relation to anxiety and depression: evidence from a large population survey: the HUNT study. European Psychiatry: J Assoc Eur Psychiatrists 2008; 23(2):77-84.
24. Lundesgaard E., Skurtveit S., Tverdal A., Hartz I. Disability pension predict use of anxiolytics and/or hypnotics 20 years later - a prospective study. Pharmacoepidemiol Drug Safety 2008; 17: S93.
25. Sogaard AJ, Selmer R., Bjertness E., Thelle D. The Oslo Health Study: the impact of self-selection in a large, population-based survey. Int J Equity Health 2004; 3(1):3.
26. Kleinbaum DG, Morgenstern H., Kupper LL Selection bias in epidemiologic studies. Am J Epidemiol 1981; 113(4):452-63.
27. Van den Brandt PA, Petri H., Dorant E., Goldbohm RA, Van de CS. Comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl Sci 1991; 13(2):91-6.
28. National Institute for Health and Clinical Excellence. Management of anxiety (panic disorder with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. London: NICE guidelines; 2004 (amended 2007). http://www.nice.org.uk/Guidance/CG22 (accessed 3 February 2009).
29. Neutel CI The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005; 17(3):189-97.